

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/146157/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Chinnery, Patrick F., Bonnet, Marion , Cave, Alison, Hofer, Matthias P., Lamb, Alastair, McConkey, Glenn A., Medcalf, Nicholas, Smith, Stephen P., Tsakok, Teresa, Watson, Robert, Webster, Steve and You, Tao 2021. Choosing drugs for UK COVID-19 treatment trials. *Nature Reviews Drug Discovery* 10.1038/d41573-021-00203-7


Publishers page: <http://dx.doi.org/10.1038/d41573-021-00203-7>

Please note:


Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.





Supplementary Figure 1 | **Drug prioritization into the UK clinical trials platforms and the UK Covid 19 therapeutics advisory panel (UK-CTAP).** Following nomination through the open online portal, the independent due diligence team established the knowledge base for a given candidate, specialist subgroups then contextualized that knowledge with expert opinion, and UK-CTAP considered all of the information to create a balanced portfolio. The due diligence team included clinical pharmacology, immunology, virology, and regulatory expertise, and in-house pharmacokinetic and pharmacodynamic modelling. The team was assembled through rapid secondments from universities, the NHS, regulatory authorities and the private sector within a matter of weeks. Data were gathered from diverse data sources including published literature, pre-prints, international databases, and through international links with the US National Institutes for Health, Wellcome, the European Clinical Research Infrastructure Network and the World Health Organisation.



Supplementary Figure 2 | Summary of the work of the UK Covid 19 therapeutics advisory panel (UK-CTAP).